PT - JOURNAL ARTICLE AU - Al Assaad, Majd AU - Hadi, Kevin AU - Levine, Max F. AU - Guevara, Daniela AU - Patel, Minal AU - Tranquille, Marvel AU - King, Abigail AU - Otilano, John AU - Semaan, Alissa AU - Gundem, Gunes AU - Medina-Martínez, Juan S. AU - Sigouros, Michael AU - Manohar, Jyothi AU - Kuo, Hui-Hsuan AU - Wilkes, David C. AU - Andreopoulou, Eleni AU - Chapman-Davis, Eloise AU - Tagawa, Scott T. AU - Sboner, Andrea AU - Ocean, Allyson J. AU - Shah, Manish AU - Papaemmanuil, Elli AU - Sternberg, Cora N. AU - Holcomb, Kevin AU - Nanus, David M. AU - Elemento, Olivier AU - Mosquera, Juan Miguel TI - Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer Cohort AID - 10.1101/2024.06.28.24309592 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.28.24309592 4099 - http://medrxiv.org/content/early/2024/06/30/2024.06.28.24309592.short 4100 - http://medrxiv.org/content/early/2024/06/30/2024.06.28.24309592.full AB - Purpose Homologous recombination deficiency (HRD) impacts cancer treatment strategies, particularly the effectiveness of PARP inhibitors. However, the variability different HRD assays has hampered the selection of oncology patients who may benefit from these therapies. Our study aims to assess the whole genome landscape to better define HRD in a pan-cancer cohort and to contribute to harmonization of HRD detection.Methods We employed a whole-genome sequencing WGS HRD classifier that included genome-wide features associated with HRD to analyze 580 tumor/normal paired pan-cancer samples. The HRD results were correlated retrospectively with treatment responses and were compared with commercial HRD tests in a subset of cases.Results HRD phenotype was identified in 62 samples across various cancers including breast (19%), pancreaticobiliary (17%), gynecological (15%), prostate (8%), upper gastrointestinal (GI) (2%), and other cancers (1%). HRD cases were not confined to BRCA1/2 mutations; 24% of HRD cases were BRCA1/2 wild-type. A diverse range of HRR pathway gene alterations involved in HRD were elucidated, including biallelic mutations in FANCF, XRCC2, and FANCC, and deleterious structural variants. Comparison with results from commercial HRD assays suggests a better performance of WGS to detect HRD, based on treatment response.Conclusion HRD is a biomarker used to determine which cancer patients would benefit from PARPi and platinum-based chemotherapy. However, a lack of harmonization of tests to determine HRD status makes it challenging to interpret their results. Our study highlights the use of comprehensive WGS analysis to predict HRD in a pan-cancer cohort, elucidates new genomic mechanisms associated with HRD, and enables an accurate identification of this phenotype, paving the way for improved outcomes in oncology care.Competing Interest StatementKevin Hadi, Max F. Levine, Gunes Gundem, Juan S. Medina-Martinez, and Elli Papaemmanuil are Isabl, Inc. employees.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by Weill Cornell Medicine IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes